New stent retriever devices.

N. C. Beadell, Helmi Lutsep

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Acute ischemic stroke (AIS) is among the leading causes of adult death and number one cause of severe disability in the United States. In 1995 physicians had their first available Food and Drug Administration (FDA) approved treatment for AIS in the form of intravenous tissue plasminogen activator (IV-tPA). Since then, there has been an explosion of interest into endovascular mechanical thrombectomy as a potential treatment of stroke. Beginning in 2004 with the Merci Retriever, there have been multiple devices tested for this purpose. In 2012, the FDA approved two new devices-the Trevo Pro and Solitaire stent retrievers-after they were shown to have superior rates of recanalization when compared to the Merci device. In this article we will highlight the similarities and differences in the devices themselves, and the trials that brought them into use. Lastly, we will briefly touch on the future of mechanical embolectomy and considerations for future trial designs and patient selection.

Original languageEnglish (US)
Pages (from-to)333
Number of pages1
JournalCurrent Atherosclerosis Reports
Volume15
Issue number6
StatePublished - Jun 2013

Fingerprint

Stents
Equipment and Supplies
Stroke
United States Food and Drug Administration
Embolectomy
Thrombectomy
Explosions
Tissue Plasminogen Activator
Patient Selection
Cause of Death
Physicians
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

New stent retriever devices. / Beadell, N. C.; Lutsep, Helmi.

In: Current Atherosclerosis Reports, Vol. 15, No. 6, 06.2013, p. 333.

Research output: Contribution to journalArticle

Beadell, NC & Lutsep, H 2013, 'New stent retriever devices.', Current Atherosclerosis Reports, vol. 15, no. 6, pp. 333.
Beadell, N. C. ; Lutsep, Helmi. / New stent retriever devices. In: Current Atherosclerosis Reports. 2013 ; Vol. 15, No. 6. pp. 333.
@article{b86aacc5fe2b4f41b8d19f787677fcb3,
title = "New stent retriever devices.",
abstract = "Acute ischemic stroke (AIS) is among the leading causes of adult death and number one cause of severe disability in the United States. In 1995 physicians had their first available Food and Drug Administration (FDA) approved treatment for AIS in the form of intravenous tissue plasminogen activator (IV-tPA). Since then, there has been an explosion of interest into endovascular mechanical thrombectomy as a potential treatment of stroke. Beginning in 2004 with the Merci Retriever, there have been multiple devices tested for this purpose. In 2012, the FDA approved two new devices-the Trevo Pro and Solitaire stent retrievers-after they were shown to have superior rates of recanalization when compared to the Merci device. In this article we will highlight the similarities and differences in the devices themselves, and the trials that brought them into use. Lastly, we will briefly touch on the future of mechanical embolectomy and considerations for future trial designs and patient selection.",
author = "Beadell, {N. C.} and Helmi Lutsep",
year = "2013",
month = "6",
language = "English (US)",
volume = "15",
pages = "333",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - New stent retriever devices.

AU - Beadell, N. C.

AU - Lutsep, Helmi

PY - 2013/6

Y1 - 2013/6

N2 - Acute ischemic stroke (AIS) is among the leading causes of adult death and number one cause of severe disability in the United States. In 1995 physicians had their first available Food and Drug Administration (FDA) approved treatment for AIS in the form of intravenous tissue plasminogen activator (IV-tPA). Since then, there has been an explosion of interest into endovascular mechanical thrombectomy as a potential treatment of stroke. Beginning in 2004 with the Merci Retriever, there have been multiple devices tested for this purpose. In 2012, the FDA approved two new devices-the Trevo Pro and Solitaire stent retrievers-after they were shown to have superior rates of recanalization when compared to the Merci device. In this article we will highlight the similarities and differences in the devices themselves, and the trials that brought them into use. Lastly, we will briefly touch on the future of mechanical embolectomy and considerations for future trial designs and patient selection.

AB - Acute ischemic stroke (AIS) is among the leading causes of adult death and number one cause of severe disability in the United States. In 1995 physicians had their first available Food and Drug Administration (FDA) approved treatment for AIS in the form of intravenous tissue plasminogen activator (IV-tPA). Since then, there has been an explosion of interest into endovascular mechanical thrombectomy as a potential treatment of stroke. Beginning in 2004 with the Merci Retriever, there have been multiple devices tested for this purpose. In 2012, the FDA approved two new devices-the Trevo Pro and Solitaire stent retrievers-after they were shown to have superior rates of recanalization when compared to the Merci device. In this article we will highlight the similarities and differences in the devices themselves, and the trials that brought them into use. Lastly, we will briefly touch on the future of mechanical embolectomy and considerations for future trial designs and patient selection.

UR - http://www.scopus.com/inward/record.url?scp=84891427516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891427516&partnerID=8YFLogxK

M3 - Article

C2 - 23625187

AN - SCOPUS:84891427516

VL - 15

SP - 333

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 6

ER -